Tech Company Financing Transactions
Modifi Bio Funding Round
Modifi Bio, based in New Haven, secured $4.3 million from Advantage Capital Partners, BrightEdge and Connecticut Innovations.
Transaction Overview
Company Name
Announced On
10/17/2023
Transaction Type
Venture Equity
Amount
$4,300,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to further advance its lead molecules towards IND-enabling studies and phase I clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Church St.
New Haven, CT 06510
USA
New Haven, CT 06510
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Modifi Bio, we are changing the oncology treatment paradigm. Bypassing the conventional approach of indirectly targeting proteins in cancer cells, Modifi Bio is redefining the rules of oncology treatment: eradicating cancer via direct DNA modification. Our novel platform demonstrates powerful anti-tumor activity in glioma and many other cancers with intrinsic DNA repair defects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Ranjit Bindra
Co-Founder
Seth Herzon
Co-Founder
Kingson Lin
Co-Founder
Kevin Rakin
Browse more venture capital transactions:
Prev: 10/17/2023: Amplifier Therapeutics venture capital transaction
Next: 10/17/2023: Done Deal venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs